文献速递类风湿关节炎

flares对类风湿关节炎患者依那西普维持、减量或停用后影像学进展的影响

Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

本研究基于随机对照试验的事后分析,比较了类风湿关节炎(RA)患者在接受依那西普(ETN)减量或停用后,是否发生flare对影像学进展的影响。结果显示,接受甲氨蝶呤(MTX)单药治疗的患者flare和影像学进展的发生率均显著高于继续联合治疗者;在联合治疗组中,发生flare的患者影像学进展率更高。提示生物制剂减量/停用后flare可能伴随结构损伤进展,需密切监测。

要点

  • ETN减量/停用后发生flare的患者影像学进展风险更高
  • MTX单药组flare和影像学进展发生率均显著高于联合治疗组
  • 生物制剂减量策略需密切监测复发迹象

核心结论

  • 在RA患者中,生物制剂减量或停用后发生的flare可能是影像学进展的后果。
  • 若采取减量/停用策略,需仔细监测复发迹象。

研究设计与样本

  • 36周开放标签诱导期:活动性RA患者接受ETN 50 mg联合MTX每周一次治疗。
  • 达到持续低疾病活动度的患者随机进入52周双盲维持期,分为ETN 50 mg+MTX、ETN 25 mg+MTX或安慰剂+MTX。
  • 事后分析比较有无flare患者的影像学进展(Δ改良总Sharp评分≥0.5单位/年)。

主要发现

  • 双盲期内,MTX单药组flare(DAS28复发)发生率显著高于全剂量/减剂量联合治疗组(62% vs 21%;P < 0.0001)。
  • MTX单药组影像学进展发生率显著高于联合治疗组(17% vs 9%;P < 0.001)。
  • 在全剂量/减剂量联合治疗组中,以CDAI和SDAI复发定义flare的患者影像学进展率高于无flare者(P < 0.01)。

关键数值与推荐

  • 影像学进展定义为Δ改良总Sharp评分≥0.5单位/年。
  • flare主要分析基于DAS28复发,敏感性分析基于CDAI和SDAI复发。

临床怎么用

  • 对RA患者减少或停用生物制剂DMARD时,应密切监测复发迹象。
  • 发生flare可能提示影像学进展风险,需考虑加强监测或调整治疗。

局限性

  • 本研究为事后分析。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The structural consequences of flare after dose reduction/discontinuation of biologic DMARDs in patients with RA who achieve remission are unclear. We compared the incidence of radiographic progression in patients with RA who did and did not experience flare after etanercept (ETN) reduction/withdrawal. METHODS: Eligible adults with moderately active RA despite MTX received ETN 50 mg plus MTX weekly in a 36-week, open-label induction period; patients achieving sustained low disease activity by week 36 were randomized to ETN 50 mg plus MTX, ETN 25 mg plus MTX, or placebo plus MTX in a 52-week, double-blind maintenance period. In post hoc analyses, radiographic progression (Δ modified total Sharp score ⩾0.5 units/year) was compared in patients with and without flare [based on DAS28 relapse (main analysis), and clinical disease activity index and simplified disease activity index relapse (sensitivity analyses)]. Findings from patients receiving full- and reduced-dose combination therapy were pooled for comparison with those from patients receiving MTX only. RESULTS: Significantly more patients receiving MTX monotherapy experienced flare, defined as DAS28 relapse (62% vs 21%; P < 0.0001) and radiographic progression (17% vs 9%; P < 0.001), than patients receiving full-/reduced-dose combination therapy in the double-blind period. Patients with flare defined as clinical disease activity index and simplified disease activity index relapse had higher rates of radiographic progression than those without flare in the full-/reduced-dose combination therapy group (P < 0.01). CONCLUSION: Radiographic progression may be a consequence of flare after biologic DMARD dose reduction/withdrawal in patients with RA. If these approaches are taken, careful monitoring for signs/symptoms of relapse is needed. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT00565409.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Smolen JS, Pedersen R, Jones H, et al. Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis. Rheumatology (Oxford). 2020. PMID: 31257453. doi:10.1093/rheumatology/kez224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。